Cognidox launches aggressive growth strategy after acquisition by US company

The acquisition has been inspired by Recur's plans to invest in growth and AI capabilities for Life Science and Hi-Tech markets. Cognidox will continue to operate from its Cambridge HQ.

Cognidox provides electronic Quality Management System (eQMS) software used by life sciences, medical device and hi-tech product development companies.

A spin-out from Cambridge’s Silicon Fen innovation cluster, it helps companies manage design documentation, quality processes and regulatory compliance for ISO, FDA and many other standards. The company has grown its user base by more than 50 per cent over the past two years while maintaining profitability.

Henry Jefferies, Founder and CEO of Recur, said: “Cognidox is the quality management partner of choice for many of the best-known names in life sciences, medical devices and high-tech product development. We believe they have built the industry’s most configurable solution and we’re excited to help them grow and add AI capabilities to the product.”

Joe Byrne, CEO of Cognidox, added: “We’re delighted to be joining forces with Recur. They have a deep understanding of how to grow industry-specific software products without losing what makes them special. Their AI-driven approach and operational depth stood out to us from day one and we’re excited for their support as we continue to innovate and deliver an outstanding product for our customers.”

“While we’re not disclosing the transaction value we are happy with the outcome. Our headquarters are at Barclays Eagle Labs, Chesterton Road, Cambridge — it’s been a great base and we’re staying put.

“We’re 18 people total with 11 Cambridge-based and the rest across the UK, Malta, Romania, Portugal and Belarus. Post-deal we’re stepping on the gas. We’re adding roles in Cambridge in product/engineering, AI/ML, and customer success, and we’ll scale go-to-market using Recur’s US footprint.

“Expect broader life-sciences coverage (beyond medical devices into biotech/pharma/CRO/CMO) and AI-driven features that cut compliance overheads and accelerate audits. The focus is fast growth with discipline: invest where it moves the needle, keep the lean model that’s served us well.”